Showing results (151-160 of 194) with videos related to
Sort By:
Pageof 20
Biorxiv : the Preprint Server for Biology|June 9, 2023
The landscape of drug sensitivity and resistance in sarcomaAhmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCTWilliam D Tap, Arun S Singh, Stephen Patrick Anthony, et al.JAMA Network Open|December 17, 2025
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical TrialJohn Nikitas, Joseph K Kendal, Ricky R Savjani, et al.Biochemical and Biophysical Research Communications|September 1, 2018
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanomaKei Kawaguchi, Takashi Higuchi, Shukuan Li, et al.Biochemical and Biophysical Research Communications|October 8, 2018
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse modelTasuku Kiyuna, Yasunori Tome, Takashi Murakami, et al.Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.Nature|November 28, 2014
PD-1 blockade induces responses by inhibiting adaptive immune resistancePaul C Tumeh, Christina L Harview, Jennifer H Yearley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.The New England Journal of Medicine|February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibJeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.The New England Journal of Medicine|June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid, Caroline Robert, Adil Daud, et al.Pageof 20